bristol-my squibb compani bm engag discoveri develop licens manufactur market distribut
sale pharmaceut nutrit product compani two segment pharmaceut nutrit
pharmaceut segment made global pharmaceut intern consum medicin busi nutrit
segment consist mead johnson nutrit mead johnson primarili infant formula children nutrit busi
januari compani complet divestitur bristol-my squibb medic imag medic imag avista capit
partner june bm acquir kosan bioscienc inc develop oncolog product august compani
complet divestitur convatec busi cidron healthcar limit affili nordic capit fund vii
decemb bm complet sale brand busi egypt glaxosmithklin
rank
return equiti
price book
incom statement summari figur billion
global peer group analysi figur usd
merck co
compani
merck co
compani
hi
long-term fundament rank
rank number list
pharmaceut compani trade today unit state
market capit billion
pharmaceut compani highest total
asset highest revenu
within sector rel moder price-to-earnings high p/
strong rel roe roa
compani paid dividend last twelv month
dividend yield high
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
bristol-my squibb compani place bss rank nyse perform past year percentil rank
bristol-my squibb compani new entrant boston consult group list top innov compani rank
rank mcap march pwc top global compani improv year rank
march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
product wast product carbon product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
indic exponenti move averag ema
minu ema posit suggest
bullish signal ema well
ema rise anoth bullish signal
 stock trade four-month high today
rel yield stock defin yield
divid averag yield dividend yield stock
 suggest stock
under-valued dividend yield term
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return capit employ versu sector averag
market averag
also follow criteria set benjamin graham
dividend yield least two-third triple-a bond yield
stock dividend yield time triple-a bond yield
total debt equal less twice net quick liquid
valu total debt billion time net
liquid valu billion
dividend yield time triple-a bond yield
benchmark set benjamin
growth quarterli revenu net incom
pcp quarterli revenu million
million
pcp quarterli net profit turnaround million
million
ebit margin posit increas
past year
turnov quarter
return equiti
return asset
price premium volum
weight averag price past year
premium greater three time
suggest topish level cautiou buy current
fall rise last three month number fall
outnumb rise
nyse market stock unit trade
today stock rel strength
mean under-perform market
price/map lower
price/map
price map ratio past day
ratio time suggest
downsid map lower
map anoth bearish indic
price risen upper bolling band
stock also overbought accord
 indic
price-to-earnings versu sector averag
market averag estim share trade
current year price-to-earnings forward year price-to-earnings
strengthen
year-to-d ytd close
today compar
risen ytd rel price chang
trail month slump past
past year close
today compar risen
period rel price chang
valu invest year ago vs
 includ capit loss
dividend reinvest
past three year fall
year bristol-my squibb compani nyse fallen
past three year close
today compar risen
period rel price chang
price/sal versu sector averag market
averag estim share trade
current year price/sal forward year price/sal
price book higher averag
total nyse market estim share trade
current year price book forward year price
book
 ratio defin jame tobin mcap divid
total asset compar rest market
stock overvalu rank bottom stock
valu ratio
averag annual compound return share price
last year under-perform averag
annual compound return
return equiti versu sector averag
market averag
return asset versu sector averag
net profit margin averag last year
lower sector averag suggest low
margin safeti
per du pont analysi return equiti
lower sector averag comput net
profit margin time asset turnov sales/asset
stock score mere set
posit net incom posit oper cash-flow good qualiti
earn oper cash-flow exce net incom reduct
total share issu
trail twelv month price-to-earnings cyclic
adjust price earn cape well cape
histor averag last year
cape develop economist robert shiller base
methodolog benjamin graham david dodd
smooth earn across period base move
averag quarter
earn yield less benchmark yield
earn yield bond yield
price sale
price book valu
stock trade low
high averag daili volatil place
stock quartil market mean mildli volatil
past year averag daili volum jump million share million share turnov period decreas year
month month indic larger number specul share regist make long-term invest less safe
price increas fuell averag volum
price decreas fuell averag volum
price increas averag volum
price decreas averag volum
result report annual
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
author million share issu outstand
liquid valu per share
common stock par valu per share author billion
share billion issu
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock million common share
million common share
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
loss/ gain equiti invest
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net use /provid invest activ
issuanc long-term debt
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
increas equival
equival begin year
equival end year
earn cont op margin
annual report bristol myer squibb net profit
nyse report net profit year-end decemb
previou year
major chang compar previou year
total revenu
ebit margin
ebit total asset
good sold sale
profit tax sale
sale market expens sale
debt equiti
total liabil total asset
work capit total asset
retain earn total asset
total current asset total asset
net tangibl asset per share
total non-curr asset total asset
current debtor total asset
fix asset total asset
total revenu total asset steadi
tax expens sale
current ratio steadi
intang total asset
fig year-on-year comparison per share figur
fig year-on-year comparison perform ratio
total debt net tangibl asset
total liabil ebitda
total liabil oper
current ratio
common size ratio asset
total non-curr asset total asset
total current asset total asset
intang total asset
current debtor total asset
fix asset total asset
common size ratio sale
good sold sale
profit tax sale
sale market expens sale
tax expens sale
fig five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound annual
growth rate compound-annual-growth-rate averag total revenu net profit ebitda
fig five-year record ebitda oper profit net profit roe roa roce
net profit margin average figur
return equiti
return asset
return capit employ
result report
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
commit conting
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
loss/ gain equiti invest
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net use invest activ
issuanc long-term debt
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
net decreas /increas equival
equival begin period
equival end period
half-yearli report sequenti growth
interim report half year report fall half-yearli net profit
nyse announc net profit half year-end june
compar previou correspond period pcp jun year-over-year revenu net profit
pcp growth ep
pcp growth revenu
pcp growth net profit
profit tax
oper cash flow
sale
past year incom tax profit tax increas
base issu equiti share market
capitalis billion nyse largest
compani total revenu
today announc quarterli dividend
per share ex dividend date thursday januari
payabl friday februari
januari bristol-my squibb acquir celgen
myer squibb compani nyse celgen corpor
celg today announc enter
definit merger agreement bristol-my squibb
acquir celgen cash stock transact
equiti valu approxim billion
detail click
taisho hold co ltd purchas
taisho pharmaceut hold co ltd taisho
offer purchas bristol-my squibb upsa consum
health busi billion upsa develop deliv
import consum medicin patient franc across
europ addit countri
detail click
januari food drug
pomalidomid dexamethason new
immunotherapi combin certain patient
relaps refractori multipl myeloma
compani nyse today announc food
drug administr fda approv emplic elotuzumab
inject intraven use combin pomalidomid
dexamethason epd treatment adult patient
multipl myeloma receiv least two prior
therapi includ lenalidomid proteasom
demonstr benefit patient relaps refractori
multipl myeloma doubl median progression-fre
surviv overal respons rate orr versu
pomalidomid dexamethason
detail click
taisho hold co ltd purchas
compani nyse today announc taisho
pharmaceut hold co ltd taisho offer
busi billion upsa develop deliv import
consum medicin patient franc across europ
detail click
full year financi result
result fourth quarter full year
highlight strong demand opdivo nivolumab eliqui
apixaban robust oper perform across
proud result base superior
commerci perform priorit brand import
scientif advanc continu diversifi pipelin
detail click
nyse today announc ep guidanc full-year
bristol-my squibb provid ep guidanc
rang non-gaap ep guidanc rang
non- guidanc
assumpt includ combin dilut
upsa divestitur
detail click
nyse today announc ep guidanc full-year
bristol-my squibb provid ep guidanc
rang non-gaap ep guidanc rang
non- guidanc
assumpt includ combin dilut
upsa divestitur
detail click
januari event calendar bristol-my squibb take
part credit suiss confer
compani nyse take part credit suiss annual
health confer wednesday novemb
scottsdal az chri boerner chief commerci offic
answer question compani mt et
detail click
januari event calendar bristol-my squibb
particip annual morgan healthcar
compani nyse today announc giovanni caforio
chairman chief execut offic join mark all
chairman chief execut offic celgen firesid
chat annual morgan healthcar confer
detail click
dasatinib tablet approv combin
chemotherapi certain pediatr patient
compani nyse today announc food
drug administr fda expand indic
sprycel regist dasatinib tablet includ treatment
pediatr patient one year age older newli
lymphoblast leukemia combin
sprycel second-gener tyrosin
kinas inhibitor approv patient popul
detail click
chmp opinion recommend sprycel dasatinib
pediatr patient newli diagnos philadelphia
compani nyse today announc committe
medicin product human use chmp european
medicin agenc recommend expand approv
sprycel dasatinib combin chemotherapi includ
treatment pediatr patient newli diagnos
detail click
decemb bristol-my squibb boston
medic center announc research collabor
investig marker immuno-oncolog respons
squibb compani nyse boston medic center
multi-year joint research studi identifi analyz potenti
sensit resist marker patient treat
detail click
januari entri materi
januari bristol-my squibb compani bm
burgundi merger sub inc wholli own subsidiari bm
merger sub enter agreement merger
merger agreement celgen corpor celgen
merger agreement provid among thing
term subject condit set forth therein merger sub
merg celgen celgen surviv
wholli own subsidiari bm merger
merger share celgen common stock issu
outstand immedi prior effect time merger
certain exclud share describ merger
agreement automat convert right
receiv cash without interest one share bm
common stock one tradeabl conting valu right
cvr repres right receiv cash
specifi set mileston achiev set forth cvr
agreement defin describ
complet merger subject customari close
condit includ adopt merger agreement
major holder outstand share celgen
common stock approv issuanc bm common
stock issu merger major vote cast
bm stockhold matter approv list
new york stock exchang bm common stock cvr
issu merger expir earli termin
applic wait period hart-scott-rodino
anti-trust improv act amend
approv merger anti-trust law specifi
jurisdict accuraci parti represent
warranti subject certain materi standard set forth
merger agreement complianc materi
respect parti oblig merger
either celgen bm may termin merger agreement
certain circumst includ merger
complet januari subject extens either
parti certain circumst event requir
regulatori approv obtain celgen stockhold
fail adopt merger agreement bm stockhold fail
approv share issuanc connect merger
government author compet jurisdict issu
final non-appeal government order prohibit merger
parti breach represent warranti
coven merger agreement way would entitl
parti seek termin merger agreement
consumm merger subject right breach
parti cure breach subject complianc specifi
process notic requir parti termin
merger agreement order enter agreement provid
case celgen compani superior propos
case bm parent superior propos defin
merger agreement parti board
director chang recommend favor
detail click
decemb bristol-my squibb
biomedicin announc research collabor advanc
ltd headquart tokyo ceo haruo naito eisai
announc multi-year research collabor focus
splice platform provid power respons
detail click
decemb bristol-my squibb vedanta
bioscienc announc new clinic collabor
evalu opdivo nivolumab patient
advanc metastat cancer
bristol-my squibb compani nyse vedanta
bioscienc today announc clinic trial collabor
immun checkpoint inhibitor opdivo combin vedanta
consortium patient advanc metastat cancer
rang preclin model cancer includ
sensit resist checkpoint inhibit
shown induc cell potenti immun system
attack tumor cell significantli amplifi effect anti-
detail click
decemb bristol-my squibb transfer
billion pension liabil
compani nyse today announc transfer
billion pension oblig full termin
 retir incom oblig
distribut combin lump sum
particip elect payment purchas
group annuiti contract athen annuiti life compani
wholly-own insur subsidiari
hold ltd nyse remain liabil
detail click
jose baselga resign bristol myer squibb
director resign take effect sep
boerner execut vice presid august
appoint christoph boerner
execut vice presid appoint take effect aug
report buy sell trail month continu
share
report institut buy sell share
hold end quarter
report hold institut decemb
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
usd valu
new york mellon corp
state tennesse treasuri
new patent issu us pto
view detail click patent link
fc fusion protein compris novel linker arrang
quinazolin potassium ion channel inhibitor
triazolopyridin inhibitor myeloperoxidas
substitut aza benzofuran compound treatment hepat
macrocycl factor xia inhibitor
substitut tetrahydroisoquinolin compound factor xia inhibitor
ipilimumab variant enhanc adcc
method treat immun diseas administ antibodi polypeptid specif bind
carbazol compound use bromodomain inhibitor
therapeut use modifi polypeptid
antibodi tigit
compound anti-cancer agent
fuse pyridin kinas inhibitor
quinuclidin compound nicotin acetylcholin receptor ligand
treatment melanoma use antibodi antibodi
antibodi
diamid macrocycl factor xia inhibitor
compound treatment hepat
antibodi bind peptidoglycan recognit protein
method select bind protein
compound use immunomodul
cancer immunotherapi disrupt signal
benzofuran substitut primari benzamid hcv inhibitor
cyclic urea inhibitor rock
benzofuran compound treatment hepat
benzofuran substitut bicycl secondari benzamid hcv inhibitor
lactam inhibitor rock
five-memb heterocycl use serin proteas inhibitor
tricycl compound anti-cancer agent
heterocycl compound use inhibitor tnf
apj agonist
substitut tetrahydrocarbazol carbazol carboxamid compound
process intermedi make tubulysin analog
antibodi use thereof
benzofuran substitut secondari benzamid hcv inhibitor
diamid macrocycl fxia inhibitor
combin antibodi antibodi treat tumor
tubulysin analog method make use
antibodi use thereof
carbamoyloxymethyl triazol cyclohexyl acid lpa antagonist
mammalian cell cultur process protein product
method treat dermatomyos polymyos administ solubl molecul
carbazol compound use bromodomain inhibitor
imidazothiadiazol imidazopyrazin deriv proteas activ receptor inhibitor
treat platelet aggreg
mammalian cell cultur process protein product
heteroaryl substitut pyrrolotriazin amin compound inhibitor
carbazol tetrahydrocarbazol compound use inhibitor btk
antibodi use thereof
heteroaryl substitut pyridyl compound use kinas modul
pyrrolidin modul treatment diseas diabet
substitut factor xia inhibitor
amide-substitut heterocycl compound use modul and/or ifn alpha
method treat express cancer
antibodi use
alkyl-amide-substitut pyridyl compound use modul and/or ifn alpha
radioligand imag receptor
lactam-contain compound deriv thereof factor xa inhibitor
substitut pyridinon inhibitor
enantioselect synthesi pyrroloindol compound
imidazo-pyridazin deriv casein kinas delta inhibitor
furopyridin compound treatment hepat
dihydropyridon factor xia inhibitor
substitut tetrahydroisoquinolin compound factor xia inhibitor
phthalazinon isoquinolinon rock inhibitor
method reduc glycoprotein aggreg
ammonium deriv treatment hepat
crystallin form factor xia inhibitor
cyanoamino aza benzofuran compound treatment hepat
triazolopyridin triazolopyrimidin inhibitor myeloperoxidas
target therapeut base engin protein bind egfr
compound treatment hepat
tricycl pyrido-carboxamid deriv rock inhibitor
composit monoval bind method use
aryl dihydropyridinon piperidinon inhibitor
spirocycloheptan inhibitor rock
macrocycl benzodiazepin dimer conjug thereof prepar use
macrocycl factor xia inhibitor
macrocycl inhibitor protein/protein interact
compound use immunomodul
macrocycl molecul hcv entri inhibitor
thiazolyl- thiadiazolyl-substitut pyridyl compound use kinas inhibitor
bristol-my squibb compani bm engag discoveri develop licens manufactur market
distribut sale pharmaceut nutrit product compani two segment pharmaceut
nutrit segment made global pharmaceut intern consum
medicin busi nutrit segment consist mead johnson nutrit mead johnson primarili
infant formula children nutrit busi januari compani complet divestitur bristol-
myer squibb medic imag medic imag avista capit partner june bm acquir kosan
bioscienc inc develop oncolog product august compani complet divestitur
convatec busi cidron healthcar limit affili nordic capit fund vii decemb
bm complet sale brand busi egypt glaxosmithklin
board manag creation sharehold valu
board director year sinc appoint
giovanni caforio chief execut offic
bristol-my squibb sinc may serv
compani board director sinc june may
assum role chairman board
ceo giovanni led compani focu research
develop transform medicin includ
lead portfolio immunotherapi fundament
chang way cancer treat leadership bm
evolv oper model order increas speed
background physician giovanni help
strengthen compani patient-focus cultur -- one driven
innov speed account passion leader
focus busi valu compani cultur
promot reward divers inclus
prior becom ceo giovanni serv chief oper
offic respons lead fulli integr world-wide
commerci organ companywid function
enterpris servic global manufactur suppli
preced work compani chief commerci
giovanni join bristol-my squibb vice presid
gener manag itali world-wide medicin group
assum ad respons greec israel
south east europ appoint
senior vice presid european market brand
commerci reloc us assum
role senior vice presid oncolog
oncolog immunolog becom presid
compani organ prior join bristol-
myer squibb giovanni spent year
number leadership posit
born educ itali giovanni receiv
univers rome
charl bancroft respons compani world-wide
financ oper includ controllership area tax
treasuri audit servic procur strateg initi
global commerci manufactur financ
oper charli also respons busi
develop strategi allow integr approach
financi plan busi develop strategi
support compani effect meet long-term
goal charli join compani kpmg
sinc held posit increas respons within financ
organ includ intern assign
commerci oper respons latin american
east africa canada japan sever countri
pacif rim charli receiv bachelor scienc degre
account drexel univers master busi
administr templ univers
dr vousden age senior group leader
franci crick institut london sinc februari chief
scientist cancer research uk cruk sinc juli
serv director cruk beatson
institut glasgow prior held leadership role
nation cancer institut maryland
dr vousden bring board year
experi lead ground break cancer research
fellow royal societi serv member
scientif advisori board centro nacion de investigacion
oncologica grail inc ludwig institut cancer research
pmv pharma swiss institut
experiment cancer research dr vousden also council
member european molecular biolog organ
mr storch age serv chief execut offic
oper depart store includ sak fifth avenu
outfitt sak kaufhof inno e-commerc
busi gilt novemb januari serv
chairman chief execut offic storch advisor
also serv chairman toy us inc februari
novemb chief execut offic toy us
februari may prior join toy us mr
storch serv vice chairman target corpor
join senior vice presid strategi
serv role increas senior next year
prior join mr storch partner mckinsey
compani director fanat inc
skill experi retail veteran
year experi mr storch provid board valuabl
busi leadership manag insight includ
expertis lead organ global oper give
keen understand issu face multi-national
busi qualiti make valu member
audit committe addit prior servic
compens committe anoth public compani posit
well serv member compens
dr sato age serv chairman board denali
therapeut inc previous serv professor
manag practic harvard busi school juli
juli juli octob serv
professor practic molecular cell biolog
dr sato retir presid vertex pharmaceut
incorpor global biotechnolog compani
respons research develop busi
corpor develop commerci oper legal
financ dr sato also serv chief scientif offic senior
vice presid research develop chair
scientif advisori board vertex name
presid
serv chairman inc
board director inc
peer health exchang inc serv co-chair
task forc scienc engin harvard univers
co-chair advisori council lifesci nyc
mr grobstein age retir vice chairman ernst
young llp independ regist public account firm
mr grobstein work ernst young
admit partner
serv vice chairman intern oper
vice chairman plan market
industri servic vice chairman
account audit servic
serv board truste execut committe
treasur central park conserv
also serv board director peer health
mr paliw age serv chairman presid
chief execut offic harman intern industri inc
connect technolog compani automot consum
enterpris market sinc juli mr paliw serv
presid chief execut offic harman sinc juli
prior join harman mr paliw serv member
group execut committe abb ltd provid industri
autom power transmiss system servic
januari june
mr paliw also serv presid global market
technolog abb ltd januari june
chairman chief execut offic abb north america
januari june presid chief
execut offic abb autom technolog divis
octob decemb
mr paliw serv board busi advisori council
farmer school busi miami univers
india busi council usibc board director also
member ceo busi roundtabl washington
 india ceo forum
mr arduini age presid chief execut
offic integra lifesci hold corpor global
medic technolog compani sinc januari current
serv member integra board director serv
presid chief oper offic integra
novemb januari join integra mr
arduini corpor vice presid presid
medic deliveri baxter healthcar prior
join baxter mr arduini work
healthcar spent much year varieti
manag role domest global busi
culmin lead global function imag busi mr
arduini also serv board director advam
advanc medic technolog associ board
director mdic medic devic innov consortium
board director nation italian american
skill experi year healthcar
industri mr arduini bring board extens leadership
busi oper experi particularli respect
manufactur sale medic technolog devic
addit mr arduini experi serv public compani
chief execut offic former chief oper offic
posit well serv member audit committe
mr laci age former non-execut chairman dave
buster entertain inc previous serv
chairman chief execut offic sear roebuck
co vice chairman chief execut offic
successor sear hold corpor
mr laci also serv vice chairman sear hold
corpor recent mr laci serv
senior advisor oak hill capit partner privat
equiti invest firm
truste fidel fund california chapter
mr laci director center advanc studi
behavior scienc stanford univers
sandi leung serv legal advisor board director
compani execut respons shape
compani legal strategi sandi also respons
secur philanthropi
acceler pace scienc government polici
regul overal global complex across industri
requir us even agil ever say sandi
legal team bring strateg valu across aspect
busi practic sound counsel guid
compani mission help patient
sandi join bristol-my squibb staff attorney
litig depart becam assist counsel
one year later name associ counsel
sandi appoint posit counsel corpor
secretari appoint act gener counsel
name gener counsel sandi
name execut vice presid
prior join compani sandi prosecutor
advic aspir manag posit
good will hard work
bring good excel judgment expertis tabl
import must great person integr
someon peopl trust peopl trust feel
comfort seek advic also respect peopl
superior everyon
sandi earn law degre boston colleg law
bachelor degre tuft univers
dr lynch serv chairman chief execut offic
massachusett gener physician organ member
massachusett gener hospit board sinc
dr lynch director yale cancer center
richard jonathan sackler professor intern
medicin yale cancer center yale school medicin
also serv physician chief smilow cancer hospit
yale-new sinc prior dr lynch
professor medicin harvard medic school chief
hematology/oncolog massachusett gener hospit dr
lynch member american associ cancer
research american societi clinic oncolog
intern associ studi lung cancer
ann powel judg global head human resourc
bristol-my squibb whose mission discov develop
deliv innov medicin help patient prevail
seriou diseas ann direct respons drive
corpor global capabl talent manag cultur
organiz effect tie directli busi
perform ann work across enterpris support bristol-
myer squibb commit creat energ work
experi cultur power divers broadli
inclus individu encourag exceed
potenti inspir make innov contribut
patient global commun live work
courag passion workforc truli inspir
drive even higher level engag make
differ live patient say ann ann industri
experi expertis lie execut compens
diversity/inclus train design deliveri talent acquisit
labor relat merger acquisit divestitur start-
mr joseph caldarella senior vice presid corpor
control bristol-my squibb co
vice presid corpor control
divis compani
technolog organ posit compani success
rapidli evolv digit age focus ensur
compani inform asset oper reliabl
access secur drive digit compani
adopt new approach digit health continu
innov approach long-term partnership key servic
excit time lead team advanc
technolog provid new opportun streamlin
live unpreced way includ manag health
paul said deliv digit capabl acceler
compani work bring innov medicin patient
challeng honor
throughout experi domest intern high-
tech consum packag good biopharmaceut
compani paul career focus strateg
leverag inform technolog drive superior perform
join bristol-my squibb paul held posit
kraft gener food hewlett-packard member
research board serv board truste
princeton healthcar system
paul bachelor degre electr engin
master degre comput scienc steven institut
technolog complet program manag
develop harvard busi school program
leadership develop imd switzerland
price period/numb period
price close today/pric close period ago rank
percentil within entir market
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
